Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical Lung Cancer(2023)10.1016/j.cllc.2022.11.007Source: DataRank Database

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) is a research paper published in Clinical Lung Cancer (2023). On theSindex it has a DataRank of 0.701. It has been cited 106 times.

N/A

0.701DataRank · unranked

Scored on demand from live citation data

106 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 7.32)OA: closedTopics (26)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.701

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (8)

Kayla Brice,Katerine Dumais,Alejandro Lopez-Cohen,Delia Wietecha,Paola A. Izquierdo

Live enrichment

PubMed:36585341 OpenAlex:https://openalex.org/W4310077405

International Association for the Study of Lung Cancer

European Society for Medical Oncology

National Comprehensive Cancer Network

American Society of Clinical Oncology

FWCI

7.32

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S1525730422002650?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525730422002650?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cllc.2022.11.007

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36585341

Fields of Study

Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsGenetic factors in colorectal cancer

MeSH Terms

Liquid BiopsyBiopsyCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMutationRetrospective StudiesBiomarkers, TumorHigh-Throughput Nucleotide Sequencing

Keywords

MedicineLiquid biopsyBiopsyConcordanceLung cancerOncologyCancerInternal medicinePathologyMolecular analysisNext Generation SequencingTargeted TherapiesActionable GenesLiquid Biopsies

Sustainable Development Goals

SDG 0: Good health and well-being

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

FAIR Checklist

DataRank Breakdown

Authors (8)

Funding (4 grants)

Impact

Open Access

Topics